Shareholders were recently treated to encouraging news from IQ-AI’s main portfolio holding in artificial intelligence. Mid-April 2023, Imaging Biometrics announced a new partnership with Prism Clinical Imaging, a provider of brain mapping software. Prism intends to integrate Imaging Biometrics’ quantitative solutions into its software product. Brain image clinical reports generated by Prism’s applications will be enhanced by quantitative analysis and maps generated by Imaging Biometrics programming. The partnership is the latest in a series of pacts for Imaging Biometrics to leverage the marketing and sales infrastructure of third-parties with complementary technologies for Imaging Biometrics’ customer targets.
We continue to rate IQAI and IQAIF at Speculative Buy with a 6.50 Gbp price target. Indeed, the Prism pact renews our enthusiasm for the Company’s prospects as it demonstrates that patience and perseverance will lead to progress in market penetration. In the run up to the year 2022 earnings report, which we expect at any time, we view the stock as a compelling value. We expect that report to confirm our expectations for continue topline growth the Company’s primary holding, Imaging Biometrics doggedly pursues customers directly and through various marketing partnerships and technology agreements.
Click on the image below to read additional details in a 10-page report dated April 27, 2023.
Please note the important disclosures and disclaimers at the end of every Crystal Equity Research publication.
Please consider the environment before printing any Crystal Equity Research publication.